UK/ICLG/P/23/0032
DE/ICLG/P/23/0013
Date of preparation: May 2023
This is a promotional meeting organised and sponsored by Incyte with the support of Envision Pharma Group. This event is for UK and EU healthcare professionals only and will involve discussion of Incyte products. Always refer to the latest version of the product label in your country.
All adverse events (AEs) should be reported to the Global Medical Information Call Centre by phone: +800 000 27423 (for local numbers see www.incyteglobalmedicalinformation.com/report-adverse-event.aspx). Alternatively, you can report AEs by email: eumedinfo@incyte.com. For UK healthcare professionals, reporting forms and information can be found at https://yellowcard.mhra.gov.uk/ or search for MHRA Yellow Card in the Google Play or Apple App Store.
The ICLUSIG® (ponatinib) SmPC is available here.
The UK ICLUSIG® (ponatinib) prescribing information is available here.
The German ICLUSIG® (ponatinib) prescribing information is available here.
Contact us at: emily.hitchcock@envisionpharma.com
Incyte, Rue Docteur-Yersin 10, 1110 Morges, Switzerland: www.incyte.com
If you would like to request further medical information, please visit: www.incyteglobalmedicalinformation.com
Please refer to Incyte's privacy policy on how Incyte processes and protects your personal information and how you may exercise your privacy rights.
Incyte privacy policy | Cvent cookie policy | Incyte terms of use
